Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.45 |
| ▸ | WNT3A | P56704 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12016989 | 0.83 | USP5 (0.60) | KMT2ANPC1RAB9AMEN1HSD17B3 | |
| SCHEMBL9419411 | 0.82 | KMT2A (0.69) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL8402203 | 0.81 | KMT2A (0.67) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL16552778 | 0.78 | KMT2A (0.83) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL4839086 | 0.77 | HSD17B3 (0.71) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL777295 | 0.77 | KMT2A (0.49) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL17723259 | 0.76 | KMT2A (0.60) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL11277802 | 0.76 | GSK3B (0.64) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL5849125 | 0.76 | KMT2A (0.78) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL10792888 | 0.76 | KMT2A (0.60) | KMT2AGSK3BNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951993-B2 | Phosphorus containing compounds as protein kinase inhibitors | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2015-02-10 | — | — | US | disclosed |
| US-20120220551-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220551-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | PPM1A, PPM1G, PPM1B | KMT2A 990/4885GSK3B 93/4885NPC1 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.